On April 13, 2017, Aiguade Bosch, Jose; Connolly, Stephen; Eastwood, Paul Robert; Gomez Castillo, Elena; Moreno Mollo, Immaculada Montserrat; Roberts, Richard Spurring; Sevilla Gomez, Sara published a patent.Application of 314021-93-7 The title of the patent was Preparation of bicyclic fused pyrimidinone and triazinone derivatives as new TRPA1 antagonists. And the patent contained the following:
The present invention relates to compounds of Formula I [G1 = C or N atom; G2, G3, G4, G5 = each independently C(Ra), N(Rb), or N; G6 = N, G7 = C atom, G8 = N atom, G9 = O atom; Ra = H, linear or branched C1-4 alkyl, halogen atom, linear or branched C1-4 alkoxy, linear or branched C1-4 haloalkyl, linear or branched C1-4 haloalkoxy, oxo, C3-7 cycloalkyl, cyano, amino, mono – or di(C1-4 alkyl)amino, or hydroxy; Rb = H or linear or branched C1-4 alkyl; L = (un)substituted linear or branched C2-4 alkylene, C(Rb):C(Rb), C3-7 cycloalkylene, (CH2)2-3-O, (CH2)1-2-C(O), (CH2)1-2-S, (CH2)1-2-S(O), CONH, CF2O, or 4- to 6-membered N-containing heterocyclylene, wherein at least one nitrogen atom is linked the G7 group; Q = each (un)substituted monocyclic or bicyclic C6-14 aryl or monocyclic or bicyclic 5- to 14-membered heteroaryl containing at least one heteroatom selected from N, O and S; or when Q = Ph, L together with Q form a 5- to 7-membered N-containing heterocyclyl fused to the Ph group; n = 0-1; the solid/dashed line = single or a double bond], pharmaceutically acceptable salts, solvates, N-oxides, tautomers, stereoisomers, or isotopically-labeled derivatives thereof:. These compounds are used in the treatment of a pathol. condition or disease susceptible to amelioration by TRPA1 channel inhibition or antagonism. The pathol. condition or disease is selected from acute and/or chronic pruritus, acute and/or chronic pain, inflammatory dermatol. diseases, respiratory disorders, gastrointestinal inflammatory disorders, and urinary tract disorders. Thus, a suspension of 0.040 g 5-methylquinazolin-4(3H)-one and 0.069 g potassium carbonate in 1.0 mL DMF was stirred at room temperature for 10 min, followed by adding a solution of 0.071 g 5-(chloromethyl)-3-[2-(4-chlorophenyl)ethyl]-1,2,4-oxadiazole in 0. 5 mL DMF, and the resulting mixture of was stirred for 3 h to give, after workup and flash chromatog., 72% 3-[[3-[2-(4-chlorophenyl)ethyl]-1,2,4-oxadiazol-5-yl]methyl]-5-methylquinazolin-4(3H)-one (II). II and 3-[[3-[2-(4-Chlorophenyl)ethyl]-1,2,4-oxadiazol-5-yl]methyl]-5-methylimidazo[5,1-f]-[1,2,4]triazin-4(3H)-one (III) inhibited the tetracycline-inducible human TRPA1 expression in CHO cells in a calcium flux assay with IC50 of 100-1,000 and <100 nM, resp. The experimental process involved the reaction of 1-Methyl-1H-pyrazolo[4,3-d]pyrimidin-7-ol(cas: 314021-93-7).Application of 314021-93-7
The Article related to fused pyrimidinone preparation trpa1 antagonist, bicyclic fused triazinone preparation trpa1 antagonist, transient receptor potential cation channel trpa trpa1 antagonist, acute chronic pruritus treatment bicyclic heterocycle, chronic acute pain treatment bicyclic heterocycle and other aspects.Application of 314021-93-7
Referemce:
Pyrazole – Wikipedia,
Pyrazoles – an overview | ScienceDirect Topics